| abstract |
The present invention can be used as an antitumour drug for testosterone-dependent tumours, in particular prostate cancer. The invention relates to a molecular compound composed of testosterone molecules chemically bonded to a chemotherapeutic radioactive iodine atom (I-124, 125 or 131) aimed at combating testosterone-dependent tumours, in particular prostate cancer, eliminating the undesirable collateral effect of known chemotherapeutic compounds, which is the destruction of rapid growth cells such as white blood cells. The main contribution of the invention is the use of testosterone as the chemotherapeutic agent carrier. In particular, a testosterone molecule chemically bonded to a radioactive iodine atom is used, which can be iodine-125, 125 or 131. |